

Financial Statements

Canadian Cancer Society -

Société Canadienne du Cancer

Year ended January 31, 2026

Contents

	Page
Independent Auditor's Report	1 - 2
Statement of Financial Position	3
Statement of Financial Activities – Operations and Externally Restricted Funds	4
Statement of Changes in Fund Balances	5
Statement of Cash Flows	6
Notes to the Financial Statements	7 - 20

Independent Auditor's Report

Doane Grant Thornton LLP
11th Floor
200 King Street West, Box 11
Toronto, ON
M5H 3T4
T +1 416 366 0100
F +1 416 360 4949

To the Members of Canadian Cancer Society - Société Canadienne du Cancer

Qualified Opinion

We have audited the financial statements of Canadian Cancer Society – Société Canadienne du Cancer (CCS), which comprise the statement of financial position as at January 31, 2026, the statement of financial activities – operations and externally restricted funds, statement of changes in fund balances and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the possible effects of the matter described in the *Basis for Qualified Opinion* section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of CCS as at January 31, 2026, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Qualified Opinion

In common with many not-for-profit organizations, CCS derives revenue from fundraising activities, which includes individual donations, corporate and planned giving, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of these revenues was limited to the amounts recorded in the records of CCS. Therefore, we were not able to determine whether any adjustments might be necessary to revenue, excess of revenue over expenses, and cash flows from operations for the years ended January 31, 2026 and January 31, 2025, current assets as at January 31, 2026 and January 31, 2025, and net assets as at February 1, 2025 and February 1, 2024 and January 31, 2026 and January 31, 2025. Our audit opinion on the financial statements for the year ended January 31, 2025 was modified accordingly because of the possible effects of this limitation in scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of CCS in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing CCS's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate CCS or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing CCS's financial reporting process.


Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of CCS's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on CCS's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause CCS to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



Toronto, Canada
June 19, 2026

Chartered Professional Accountants
Licensed Public Accountants

Canadian Cancer Society - Société Canadienne du Cancer

Statement of Financial Position

(in thousands of dollars)

As at January 31

	2026	2025
Assets		
Current assets:		
Cash	\$ 55,732	\$ 58,686
Investments (note 2)	150,668	136,302
Accounts receivable	4,769	9,139
Prepaid expenses	5,145	4,623
	216,314	208,750
Long-term investments (note 2)	18,186	17,603
Intangible assets (note 3)	990	1,019
Capital assets (note 4)	57,451	56,503
	\$ 292,941	\$ 283,875
Liabilities and Fund balances		
Current liabilities:		
Accounts payable and accrued liabilities (note 5)	\$ 17,794	\$ 14,113
Research grants payable	44,946	43,178
Deferred contributions (note 6)	27,902	32,565
Defined benefit pension liability (note 8(a))	-	1,779
	90,642	91,635
Defined benefit pension liability (note 8(a))	2,630	2,654
Defined benefit liability for post retirement benefits other than pensions (note 8(b))	14,886	15,485
	108,158	109,774
Fund balances:		
Operations fund		
Invested in intangible and capital assets (note 9(a))	58,441	57,522
Internally restricted (note 9(b))		
Operating	76,869	55,918
Research	21,048	35,103
Other	13,954	10,879
Unrestricted	3,500	3,500
Externally restricted fund (note 10)	10,971	11,179
	184,783	174,101
	\$ 292,941	\$ 283,875

Commitments (note 13)

Guarantees and contingencies (note 15)

On behalf of the Board:



Director



Director

See accompanying notes to the financial statements.

Canadian Cancer Society - Société Canadienne du Cancer

Statement of Financial Activities – Operations and Externally Restricted Funds

(in thousands of dollars)

Year ended January 31

	Operations fund		Externally restricted fund		Total	Total
	2026	2025	2026	2025	2026	2025
Revenue:						
Fundraising revenue:						
Individual donations	\$ 111,804	\$ 95,644	\$ 35	\$ 61	\$ 111,839	\$ 95,705
Planned giving	43,907	31,891	-	-	43,907	31,891
Corporate and sponsorships	14,541	15,248	-	116	14,541	15,364
	170,252	142,783	35	177	170,287	142,960
Lotteries	2,192	2,272	-	-	2,192	2,272
Government grants	27,744	24,581	-	-	27,744	24,581
Investment income (note 14)	7,117	12,565	350	715	7,467	13,280
Program user fees and other income	3,725	3,875	9	-	3,734	3,875
	211,030	186,076	394	892	211,424	186,968
Expenses:						
Mission expenses:						
Programs (note 11)	76,351	67,954	258	34	76,609	67,988
Research (note 11)	48,292	50,853	26	-	48,318	50,853
Advocacy (note 11)	5,125	5,380	-	-	5,125	5,380
	129,768	124,187	284	34	130,052	124,221
Fundraising (note 11)	58,490	52,758	-	1	58,490	52,759
Lotteries	1,355	1,282	-	-	1,355	1,282
Administration	9,980	9,542	60	60	10,040	9,602
	199,593	187,769	344	95	199,937	187,864
Excess (deficiency) of revenue over expenses before undernoted item	11,437	(1,693)	50	797	11,487	(896)
Unrealized (losses) gains on investments (note 14)	(834)	4,094	(51)	327	(885)	4,421
Excess (deficiency) of revenue over expenses	\$ 10,603	\$ 2,401	\$ (1)	\$ 1,124	\$ 10,602	\$ 3,525

See accompanying notes to the financial statements.

Canadian Cancer Society – Société Canadienne du Cancer

Statement of Changes in Fund Balances

(in thousands of dollars)

Year ended January 31

			Operations fund	Externally restricted fund	Total	Total
	Invested in intangible and capital assets	Internally restricted	Unrestricted	Externally restricted	2026	2025
Fund balances, beginning of year	\$ 57,522	\$ 101,900	\$ 3,500	\$ 11,179	\$ 174,101	\$ 168,955
(Deficiency) excess of revenue over expenses	(4,574)	-	15,177	(1)	10,602	3,525
Investment in intangible and capital assets	5,493	-	(5,493)	-	-	-
Transfer of funds (notes 9(b) and 10)	-	9,971	(9,764)	(207)	-	-
Remeasurement of defined benefit pension liability	-	-	(43)	-	(43)	(1,693)
Remeasurement of defined benefit liability for post-retirement benefits other than pensions	-	-	123	-	123	3,314
Fund balances, end of year	\$ 58,441	\$ 111,871	\$ 3,500	\$ 10,971	\$ 184,783	\$ 174,101

See accompanying notes to the financial statements.

Canadian Cancer Society - Société Canadienne du Cancer

Statement of Cash Flows

(in thousands of dollars)

Year ended January 31

	2026	2025
Operating activities		
Excess of revenue over expenses	\$ 10,602	\$ 3,525
Non-cash items:		
Amortization of intangible assets	29	28
Amortization of capital assets	4,545	4,375
Defined benefit pension expense	450	757
Post-retirement benefits expense	671	887
Gain on investments	(4,949)	(14,003)
Gain on disposal of capital assets	-	(504)
Deferred contributions recognized (note 6)	(100,619)	(84,797)
Employer defined benefit pension contributions	(2,296)	(1,070)
Employer post-retirement benefits contributions	(1,147)	(1,138)
Decrease in other long-term liabilities	-	(29)
Change in non-cash operating working capital:		
Accounts receivable	4,370	(4,860)
Prepaid expenses	(522)	(1,202)
Accounts payable and accrued liabilities	3,681	2,624
Research grants payable	1,768	3,091
Deferred contributions	95,956	88,875
	12,539	(3,441)
Investing activities		
Capital asset additions	(5,493)	(3,710)
Proceeds on sale of investments	-	30,000
Purchase of investments	(10,000)	(20,000)
	(15,493)	6,290
(Decrease) increase in cash	(2,954)	2,849
Cash, beginning of year	58,686	55,837
Cash, end of year	\$ 55,732	\$ 58,686

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

The Canadian Cancer Society – Société Canadienne du Cancer (CCS) is a national charity who works tirelessly to save lives, improve lives and drive collective action against cancer. Together with patients, volunteers, donors and communities across the country, CCS raises funds to invest in transformative cancer research, provide a caring support system for everyone affected by cancer and advocate to governments to create a healthier future for all. It takes a society to take on cancer – and CCS is leading the way.

CCS is a registered charity incorporated under the Canada Not-for-profit Corporations Act (CNCA) as an organization without share capital and is exempt from income taxes provided certain requirements under the Income Tax Act (Canada) are met.

1. Significant accounting policies

(a) Basis of presentation:

The financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations (ASNPO).

(b) Fund accounting:

The externally restricted fund reports contributions utilized for capital campaigns and endowments. Other externally restricted contributions that relate to CCS's regular operations are reported in the operations fund as deferred contributions.

The operations fund reports all other activity and includes the following balances:

- (i) Invested in intangible and capital assets representing the net book value of all intangible and capital assets, less any related debt.
- (ii) Internally restricted representing amounts that have been allocated for specific purposes by the Board of Directors.
- (iii) Unrestricted representing CCS's research, programs, advocacy, fundraising, and administration activities not accounted for in other balances.

(c) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Equity instruments that are quoted in an active market are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost unless management has elected to carry the instruments at fair value. CCS has elected to carry its pooled fund investments at fair value. The fair value of the pooled fund investments is determined based on year-end quoted market prices of the underlying assets in the pooled funds. Transaction costs incurred on the acquisition of financial instruments subsequently measured at fair value are expensed as incurred.

Financial assets measured at cost or amortized cost are regularly assessed for indicators of impairment. If there is an indication of impairment, CCS determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset, and recognizes an impairment loss if the carrying value of the financial asset is greater than the higher of the present value of the expected future cash flows, the amount that could be realized from selling the financial asset or the amount CCS expects to realize by exercising its right to any collateral.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

1. Significant accounting policies (continued)

(c) Financial instruments (continued):

If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent the adjusted value does not exceed the initial carrying value.

The investment policy of CCS prohibits investment in any derivative financial instrument arrangements for leveraging or speculative purposes. CCS may invest in derivatives to specifically hedge investment assets against currency or interest rate risk.

Financial assets and financial liabilities in related party transactions are initially measured at cost. When the financial instrument has repayment terms, cost is determined using the undiscounted cash flows of the instrument less any impairment losses recognized by the transferor. When the financial instrument does not have repayment terms, the cost of the instrument is initially measured at the exchange or carrying amount of the consideration transferred.

Financial assets and financial liabilities obtained in related party transactions are subsequently measured based on how CCS initially measured the instrument.

(d) Intangible assets:

Intangible assets are recorded at cost and are amortized on a straight-line basis over their estimated useful life. When conditions indicate an intangible asset no longer contributes to CCS's ability to provide services or that the value of future economic benefits or service potential associated with the intangible asset is less than its net carrying amount, its net carrying amount is written down to its fair value or replacement cost.

(e) Capital assets:

Purchased capital assets are recorded at cost. Contributed capital assets are recorded at fair value at the date of contribution. When conditions indicate a capital asset no longer contributes to CCS's ability to provide services or that the value of future economic benefits or service potential associated with the capital asset is less than its net carrying amount, its net carrying amount is written down to its fair value or replacement cost.

Capital assets are amortized on a straight-line basis over the following periods:

Buildings	Maximum of 40 years based on useful life
Furniture and fixtures	4 years
Computer hardware and software	3 - 5 years
Vehicles	3 years
Leasehold improvements	Lesser of lease term and useful life

Costs related to capital assets that are not available for use at year end are reflected as work in progress. As these assets are not available for use, no amortization is taken on these amounts. Once available for use, these assets will be transferred to the appropriate capital asset category at which time amortization will commence.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

1. Significant accounting policies (continued)

(f) Research grants payable:

Research grants awarded to organizations to complete research projects are recorded as research grants payable and a research expense in the year the commitment is authorized by CCS. For any authorized research grants that are discontinued, the original liability, to the extent it still exists, and any expense is reversed.

(g) Deferred contributions:

Deferred contributions represent the deferred portion of government sponsored projects, designated bequests and funds received for specific projects for which no corresponding restricted fund exists and are recognized as revenue when the related expenses are incurred.

(h) Employee future benefits:

i. Pension plan:

CCS maintains a legacy registered pension plan with a defined benefit component and a defined contribution component. The defined benefit component provides pensions based on length of service and final average earnings. The defined contribution component provides benefits based on the amount of employee and employer contributions and the rate of return on such contributions. On March 21, 2024, the Board of Directors approved the wind-up of this plan (note 8(a)).

CCS also maintains a supplemental defined benefit pension plan (non-registered plan) providing benefits above the maximums prescribed under the Income Tax Act (Canada). The non-registered pension plan is unfunded.

CCS measures the defined benefit obligations using an actuarial valuation prepared for accounting purposes based on the projected benefit method prorated on services, using various actuarial assumptions. The measurement date of the plan assets and defined benefit obligations is January 31.

ii. Post-retirement benefits other than pensions:

CCS maintains a post-retirement benefit plan for retired employees and their spouses which includes life insurance, extended health care and dental care benefits. Employees joining CCS after January 1, 2007, are not eligible for this benefit plan. The post-retirement benefit plan is unfunded.

CCS accrues its obligations under the post-retirement benefit plan as the employees render the services necessary to earn the post-retirement benefits. CCS measures the post-retirement benefit obligation using an actuarial valuation prepared for accounting purposes based on the projected benefit method prorated on services, using various actuarial assumptions. The measurement date of the post-retirement benefit obligation is January 31.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

1. Significant accounting policies (continued)

(h) Employee future benefits (continued):

CCS accounts for current service costs and finance costs under the pension and post-retirement benefits other than pension plans through the statement of financial activities. Remeasurements and other items are accounted for through the statement of changes in fund balances and include actuarial gains and losses; past service costs; and gains and losses arising from settlements and curtailments.

Actuarial gains and losses are changes in the defined benefit obligations arising from differences between actual and expected experiences and from changes in the actuarial assumptions used to determine the defined benefit obligations.

(i) Revenue and expenses:

i. Revenue:

CCS follows the restricted fund method of accounting for contributions.

Revenue from unrestricted contributions is recognized on a cash basis, with no accrual being made for amounts pledged but not received.

Endowment and externally restricted contributions for which an externally restricted fund exists are recognized as revenue in the externally restricted fund in the year in which they are received. Endowments consist of restricted contributions received by CCS where the principal gift is required to be maintained intact in perpetuity and investment income is used in accordance with the purposes established by the donors. Other externally restricted contributions consist of contributions received by CCS for capital projects. Restricted contributions received for which no fund exists are deferred and recognized when used in accordance with the intended purpose.

CCS recognizes government grants towards current expenses in the statement of financial activities when received or receivable. When government grants are restricted for a future period, CCS defers recognition until the period in which the related expenses are incurred.

Special events revenue is recognized on completion of the event.

Investment income is recognized on an accrual basis. Changes in fair value, of investments subsequently measured at fair value, are included in unrealized gains (losses) on investments in the statement of financial activities.

CCS is the beneficiary under various wills and trust agreements. As the total realizable amounts are not readily determinable, CCS recognizes such bequests when the proceeds are received or when collection of the amount is reasonably assured and reliably measurable.

Revenue from lotteries is recognized upon completion of the lottery.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

1. Significant accounting policies (continued)

(i) Revenue and expenses (continued):

ii. Expenses:

Expenses are charged to mission priorities, which include programs, research, advocacy, as well as fundraising and administration according to the activity that they benefit. Certain expenses benefit more than one category and, accordingly, are attributed to the relevant categories. In addition, certain administrative expenses are allocated to mission and fundraising activities based on an estimate of staff time related to each area of activity (note 11). A policy exists that enforces the annual review and approval of the basis of allocation for all expenses. The basis of allocation may be revised according to circumstances prevailing at any given time.

Programs' expenses consist of health promotion for Canadians (tobacco cessation, healthy eating, physical activity, reduced exposure to carcinogens, screening) and of support to cancer patients and caregivers during and beyond the cancer journey. Information, emotional and practical support programs are delivered in the community in person, by telephone, print or through the website and social media. Examples of programs include cancer prevention services such as smoking cessation programs and healthy living programs, help managing life with cancer by providing cancer information, lodging, transportation, financial assistance, wigs/prosthesis and help finding other community resources. CCS also provides safe places for community and connection for people with cancer and their loved ones through our online community CancerConnection.ca and through Camp Goodtimes.

Research expenses include research funding and the costs of supporting research programs and developing surveillance products. Research funding (projects, personnel and research centres) focuses on the advancement of knowledge in cancer risk reduction and prevention, screening, diagnosis, treatment, cure, supportive care, survivorship and end-of-life care through basic-biomedical, translational, clinical, behavioural and population-based research. Supporting research programs includes activities related to the peer-review process, program administration, research forums, advisory committees and linkage with researchers. Products developed by surveillance include the annual cancer statistics reports and activities to support the implementation of the pan-Canadian Cancer Data Strategy.

Advocacy expenses include activities related to influencing policy makers to implement public policies and programs that enable the adoption of healthy behaviours, reduction of occupational and environmental carcinogens, access to organized cancer screening programs and quality cancer care (from diagnosis to palliative care), financial support for cancer patients and caregivers and investment in cancer research. Activities include developing positions, raising public awareness, mobilizing communities, building coalitions and lobbying.

Fundraising expenses include all costs supporting the generation of fundraising revenue to provide the means to further CCS's mission. Fundraising expenses include costs related to the lotteries, which are costs related to prizes awarded, marketing and other expenses.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

1. Significant accounting policies (continued)

(i) Revenue and expenses (continued):

Administration expenses are incurred to operate CCS and its programs in a cost-effective manner while maximizing all opportunities to further CCS's mission. These include expenses related to human resources, information technology, facilities, finance and corporate governance activities, such as strategic planning, compliance and regulatory reporting, and financial planning.

(j) Donated goods and services:

The value of donated goods and services is recorded as revenue and an expense in the financial statements when the fair value can be reasonably estimated, is \$5,000 or greater, a gift agreement has been signed, and the goods and services are normally purchased and would be paid for if not donated.

CCS's programs benefit substantially from services in the form of volunteer time. The value of volunteer services is not recorded in these financial statements.

(k) Use of estimates:

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Significant items subject to such estimates and assumptions include the carrying amount of intangible and capital assets, obligations related to employee future benefits and allocation of expenses. Actual results could differ from those estimates.

(l) Cloud computing arrangements:

Accounting Guideline AcG-20, Customer's accounting for cloud computing arrangements, provides guidance on the accounting for expenditures on cloud computing arrangements. CCS elected to apply the simplification approach to account for its expenditures in its cloud computing arrangements, whereby the expenditures in all cloud computing agreements, excluding property and equipment and rights to use tangible capital assets are treated as a supply of services and expensed as CCS receives the services. Amounts paid in advance of receiving services are recognized as a prepaid expense. Amounts expensed during 2026 totaled \$6,824 (2025 - \$5,639).

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

2. Investments

Investments have been placed in independently managed portfolios which are comprised of pooled funds. The composition of pooled funds held consist of the following asset classes:

	2026	2025
Fixed income	52.32%	51.28%
Global equity	20.00%	19.88%
Private market investments	17.91%	18.35%
Canadian equity	6.66%	6.58%
Money market	3.11%	3.91%

Investments are classified as follows:

	2026	2025
Current	\$ 150,668	\$ 136,302
Long-term	18,186	17,603
	\$ 168,854	\$ 153,905

Investments classified as current can be promptly liquidated if required.

Long-term investments include pooled funds that are not available for prompt liquidation. These funds are subject to lock-in periods and are subject to the fund's discretion for liquidation or sale.

3. Intangible assets

	2026	2025
Cost	\$ 1,619	\$ 1,619
Accumulated amortization	(629)	(600)
	\$ 990	\$ 1,019

Camp Goodtimes:

CCS has an agreement with the University of British Columbia (UBC) to provide CCS with access to the UBC Loon Lake Camp. The camp facilities house the camp programs for children and teens who are undergoing or who have undergone cancer treatment, along with their siblings and families. This agreement began in January 2004 and ends on December 31, 2055, with lump-sum payments by CCS totalling \$1,619 and annual operating payments of \$154 (2025 - \$150) indexed for inflation in the future. Total lump-sum payments were capitalized and are amortized over the term of the agreement, subject to early termination rights by both parties. If this occurs, any unamortized amounts would be repaid to CCS.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

4. Capital assets

				2026	2025
	Cost	Accumulated amortization		Net book value	Net book value
Land	\$ 4,012	\$ -	\$	4,012	\$ 4,012
Buildings	78,280	34,415		43,865	44,569
Furniture, fixtures, computer hardware and software	18,319	15,536		2,783	3,348
Vehicles	352	240		112	3
Leasehold improvements	3,136	608		2,528	2,520
Work in progress	4,151	-		4,151	2,051
	\$ 108,250	\$ 50,799	\$	57,451	\$ 56,503

Work in progress of \$4,151 (2025 - \$2,051) relates to lodge renovations, office improvements and costs incurred on website upgrades to be launched at a later date. These assets are not available for use and therefore, no amortization is being recorded.

5. Accounts payable and accrued liabilities

Included in accounts payable and accrued liabilities are government remittances payable of \$279 (2025 - \$285) relating to federal and provincial sales taxes, payroll taxes, health taxes and workers' safety insurance.

6. Deferred contributions

	2026	2025
Balance, beginning of the year	\$ 32,565	\$ 28,487
Amounts received	95,956	88,875
Revenue recognized in the year	(100,619)	(84,797)
Balance, end of the year	\$ 27,902	\$ 32,565

7. Credit facilities

CCS has entered into a credit facility agreement (the Facility) with a Canadian chartered bank, used by CCS to issue letters of credit in support of its Ontario lotteries. The Facility has a maximum credit limit equal to \$10,000 and drawings are secured by cash held at the chartered bank. The Facility carries a fee of 0.45% per annum on any drawn amounts. As of January 31, 2026, CCS had letters of credit in the amount of \$971 (2025 - \$1,005) outstanding.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

8. Employee future benefit plans

(a) Defined benefit pension liability:

	Registered plan	Non- registered plan	2026	2025
Defined benefit obligation	\$ 40	\$ 2,686	\$ 2,726	\$ 26,907
Fair value of plan assets	96	-	96	22,474
Defined benefit pension (asset) liability	\$ (56)	\$ 2,686	\$ 2,630	\$ 4,433

On March 21, 2024, the Board of Directors approved the wind-up of CCS's registered plan (the registered plan) effective May 12, 2024. An actuarial valuation with an effective date of May 12, 2024, was filed with the Financial Services Regulatory Authority of Ontario (FSRAO) on November 7, 2024 which was approved by FSRAO on June 26, 2025.

Upon approval, the members of the registered plan began to receive the full value of their pension benefit and have various options to receive that benefit such as transferring the commuted value of the pension benefit in a lump sum transfer to a locked-in retirement vehicle, through the purchase of an annuity from a Canadian insurance company, or a payment of cash refunds where applicable. The options offered to each member will depend on various factors such as age, province of employment at the wind-up date, and whether the member is already in receipt of a monthly pension. Simultaneously, the pension obligations of CCS related to the registered plan are settled, discharging any further obligations of CCS with respect to the registered plan. As at January 31, 2026, two members of the registered plan remain eligible and will receive their pension benefits over the next months.

The defined benefit obligations of the non-registered pension plans as at January 1, 2026, are estimates, based on actuarial assumptions of liabilities that will be settled over a long-term time horizon. The discount rate assumption used in determining the defined benefit obligations of the plans was selected based on a review of current market interest rates of high-quality corporate bonds with cash flows that match the timing and amount of expected benefit payments. The discount rate applied for the year ended January 31, 2026, was 4.6% (2025 – 4.6%).

The actuarial valuation of the registered plan was as of the effective wind up date of May 12, 2024. The most recent actuarial valuation of the non-registered plan was as of December 31, 2025.

Effective May 12, 2024, CCS became a participating employer in the College of Applied Arts and Technology pension plan (CAAT Pension Plan). CCS accounts for its participation in the CAAT Pension Plan, a multiple employer defined benefit pension plan, as a defined contribution plan, as CCS has insufficient information to apply defined benefit plan accounting. Therefore, CCS's contributions are accounted for as if the CAAT Pension Plan is a defined contribution plan with CCS's contributions being expensed in the period they come due. Contributions to the CAAT Pension Plan made during the year by CCS amounted to \$2,750 (2024 - \$1,802). The most recent actuarial valuation filed with pension regulators as of January 1, 2026, indicated the CAAT Pension Plan had an actuarial surplus of

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

8. Employee future benefit plans (continued)

(a) Defined benefit pension liability (continued):

\$6,749,000 (2025 - \$6,141,000). The next valuation will be completed no later than January 1, 2029.

(b) Defined benefit liability for post-retirement benefits other than pensions:

The plan for post-retirement benefits other than pensions is unfunded and therefore, has no plan assets to report. The discount rate assumption used in determining the defined benefit obligation for post-retirement benefits other than pensions is selected based on a review of current market interest rates of high-quality corporate bonds with cash flows that match the timing and amount of expected benefit payments. The discount rate applied for the year ended January 31, 2026 was 4.6% (2025 – 4.5%)

The most recent actuarial valuation of the post-retirement benefit plan was as of January 31, 2025, and the next required valuation will be as of January 31, 2028.

9. Operations fund

a) Invested in intangible and capital assets

The amount invested in intangible and capital assets comprises the following amounts:

	2026	2025
Intangible assets (note 3)	\$ 990	\$ 1,019
Capital assets (note 4)	57,451	56,503
	\$ 58,441	\$ 57,522

b) Internally restricted

The internally restricted balance comprises the following reserves:

	Operating	Research	Capital and technology	Strategic	Fundraising	2026	2025
Balance, beginning of year	\$ 55,918	\$ 35,103	\$ 7,791	\$ -	\$ 3,088	\$101,900	\$ 96,429
Transfers	20,951	(14,055)	(1,954)	5,858	(829)	9,971	5,471
Balance, end of the year	\$ 76,869	\$ 21,048	\$ 5,837	\$ 5,858	\$ 2,259	\$111,871	\$101,900

- (i) An operating fund is held to address operational requirements. The Board of Directors approved a transfer of \$20,951 (2025 – \$1,505) from the unrestricted fund to the internally restricted fund bringing the total to \$76,869.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

9. Operations fund (continued)

- (ii) The Board of Directors approved a transfer of \$14,055 from the research fund to the unrestricted fund (2025 – \$6,683 from the unrestricted fund to the research fund) to bring the total to \$21,048 to ensure funding for a portion of future research commitments equal to one subsequent year's grant commitment as determined at each year-end.
- (iii) The Board of Directors approved a transfer of \$1,954 (2025 – \$2,055) from the capital and technology fund to the unrestricted fund to fund ongoing transformational digital and technology projects.
- (iv) The Board of Directors approved a transfer of \$5,858 (2025 – \$Nil) from the unrestricted fund to the strategic fund to support initiatives in the strategic plan.
- (v) The Board of Directors approved a transfer of \$829 (2025 – \$662) from the fundraising fund to the unrestricted fund to support ongoing revenue generation.

10. Externally restricted fund

	Capital campaigns	Endowments	2026	2025
Balance, beginning of the year	\$ 1,621	\$ 9,558	\$ 11,179	\$ 11,315
(Deficiency) excess of revenue over expense	(276)	275	(1)	1,124
Transfers	30	(237)	(207)	(1,260)
Balance, end of the year	\$ 1,375	\$ 9,596	\$ 10,971	\$ 11,179

11. Allocation of expenses

Certain administrative expenses are allocated to mission and fundraising activities based on an estimate of staff time related to each area of activity.

The administrative expenses which have been allocated impact the following expense categories:

	2026	2025
Programs	\$ 24,449	\$ 23,628
Research	1,459	1,410
Advocacy	1,926	1,862
Fundraising	7,215	7,748
	\$ 35,049	\$ 34,648

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

12. Ontario Smokers' Helpline

Ontario Smokers' Helpline is a confidential service operated by CCS and funded by the Ontario provincial government offering support and information about quitting smoking and tobacco use. The program provides evidence-based, non-judgemental smoking cessation support by phone, online, text message, and social media. During the fiscal year, program revenue and expenses of \$750 (2025 - \$750) were recognized by CCS.

13. Commitments

CCS has entered into various agreements with minimum aggregate annual commitments as follows:

	Premises	Equipment and other	Total
2027	\$ 1,813	\$ 14	\$ 1,827
2028	1,761	14	1,775
2029	1,768	14	1,782
2030	1,413	2	1,415
2031	1,308	2	1,310
	\$ 8,063	\$ 46	\$ 8,109

In addition, as at January 31, 2026, CCS has awarded research grants and program funding totalling \$37,275 (2025 - \$66,285), of which \$21,048 (2025 - \$35,103) is covered by the research reserve. All funding is subject to future revenue and to certain performance conditions being met.

2027	\$ 21,048
2028	8,630
2029	5,947
2030	1,650
	\$ 37,275

14. Income from investments measured at fair value

Income earned:

	2026	2025
Unrealized (losses) gains	\$ (885)	\$ 4,421
Interest and dividends income	7,347	7,563
Realized gains	120	5,717
Total income and realized gains	7,467	13,280
Total investment income	\$ 6,582	\$ 17,701

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

14. Income from investments measured at fair value (continued)

	2026	2025
Income earned on unrestricted funds		
- recognized in the operations fund	\$ 6,283	\$ 16,659
Income earned on restricted funds		
- recognized in the externally restricted fund	299	1,042
Total investment income	\$ 6,582	\$ 17,701

15. Guarantees and contingencies

CCS purchases directors' and officers' insurance. CCS has indemnified its past, present and future directors, officers, trustees, employees, volunteers and members, who sit on any duly constituted committee of CCS, against expenses (including legal), judgements and any amount actually, or reasonably incurred by them in connection with any wrongful act in which they are sued as a result of their service to CCS, if they acted honestly and in good faith with a view of the best interests of CCS.

The nature of these indemnification agreements prevents CCS from making a reasonable estimate of the maximum exposure due to the difficulties in assessing the amount of the liability, which stems from the unpredictability of future events and the unlimited coverage offered to third parties. Historically, CCS has not made any significant payments under such or similar indemnification agreements. At this time, CCS is not aware of any claims under these guarantees and, therefore, no amount has been accrued in the financial statements with respect to these guarantees.

CCS is party to legal actions arising in the ordinary course of operations. While it is not feasible to predict the outcome of these actions, it is the opinion of management that the outcome of any claims is currently not determinable. Any loss resulting from the resolution of these claims will be charged to operations in the year of resolution.

16. Related party transactions

During the fiscal year ended January 31, 2026, no member (2025 – 1 member) of the Board of Directors was in recipient of research funding through CCS's normal competitive research grant process either directly or indirectly.

17. Financial risks

Risk management relates to the understanding and active management of risks associated with all areas of CCS's activities and the associated operating environment. CCS is primarily exposed to the following financial risks: interest rate, market, foreign currency, credit and liquidity risks.

Canadian Cancer Society - Société Canadienne du Cancer

Notes to the Financial Statements

(in thousands of dollars)

January 31, 2026

17. Financial risks (continued)

(a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flow of a financial instrument will fluctuate because of changes in the market interest rate. CCS's short-term deposits and a portion of investments bear interest at various fixed rates and therefore are subject to fair value interest rate risk. CCS's other financial instruments are non-interest bearing. There has been no change to the risk exposure from 2025.

(b) Market risk

Market risk is the risk that the value of equity securities changes with stock market conditions, which are affected by general economic and market conditions. The fair value of securities will vary with developments within the specific companies or governments which issue the securities. CCS's investment in pooled funds are subject to market risk as a result of the securities in which the pooled funds are invested. CCS manages this risk through controls to monitor and limit concentration levels. There has been no change to the risk exposure from 2025.

(c) Foreign currency risk

Foreign currency risk is the risk that the fair value of securities denominated in a currency other than the Canadian dollar will be affected by changes in the value of the Canadian dollar in relation to the value of the currency in which the security is denominated. CCS's investment policies mitigate this risk by limiting concentration levels. There has been no change to the risk exposure from 2025.

(d) Credit risk

Credit risk arises from the potential that the counterparty will fail to discharge its obligations. CCS is exposed to credit risk on its fixed income investments as a default by the bond issuer would cause a financial loss for CCS. CCS mitigates this risk by restricting fixed income investments to instruments with high quality credit ratings assigned by a well-recognized credit agency, and by limiting exposure to individual investments. CCS does not consider credit risk on its accounts receivable to be significant given the nature of CCS's sources of revenue. There has been no change to the risk exposure since 2025.

(e) Liquidity risk

Liquidity risk is the risk that CCS will not be able to meet a demand for cash or fund its obligations as they come due. CCS meets its liquidity requirements by preparing and monitoring forecasts of cash flows from operations, anticipating investing and financing activities and holding assets that can be readily converted into cash. There has been no change to the risk exposure since 2025.